Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised D. Carnegie & Co in connection with a directed issue of approximately 6.5 million Class B shares
Mandate

Vinge has advised D. Carnegie & Co in connection with a directed issue of approximately 6.5 million Class B shares

April 19, 2016

Vinge has advised D. Carnegie & Co AB (publ) (”D. Carnegie”), listed on Nasdaq Stockholm, in connection with the company’s directed cash share issue of 6,539,900 Class B shares at a subscription price of SEK 72.50 per share, raising proceeds of approximately SEK 474,000,000 before transaction costs. The subscription price was determined through an accelerated book-building process. Subscribers in the share issue were approximately 60 Swedish and international institutional investors.

Vinge’s team consisted of Jesper Schönbeck, Sofie Bjärtun and André Isacson.  

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026